← All trials
NCT05132049
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 13, 2021
- Primary completion
- Jan 29, 2022
- Completion date
- Feb 4, 2022
- First posted
- Nov 23, 2021
- Last posted
- Nov 23, 2021
- Enrollment
- 42
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Dong-A PharmaceuticalLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.